@inproceedings{inproceedings, title  = {{SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of Erdafitinib (ERDA) monotherapy and ERDA and Cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC) whose tumours express FGFR gene alterations}},

 url = {{}},

 year = {{2024}},

 month = {{1}},

 author = {{Necchi A and Hussain SA and Loriot Y and de Velasco G}},

 volume = {{85}},

 journal = {{EUROPEAN UROLOGY}},

 pages = {{S427-S427}},

 note = {{Accessed on 2024/12/22}}}